| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Janja Marc | Q42815054 |
| P2093 | author name string | Matjaz Jeras | |
| Janja Zupan | |||
| P2860 | cites work | IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17 | Q84511967 |
| Human osteoclastogenic T cells and human osteoclastology | Q84819866 | ||
| Interleukin-32 promotes osteoclast differentiation but not osteoclast activation | Q21092154 | ||
| IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats | Q24294661 | ||
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis | Q24563235 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis | Q24800661 | ||
| Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications | Q24806684 | ||
| Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? | Q24814224 | ||
| Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells | Q27860460 | ||
| Bone versus immune system | Q28140389 | ||
| Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis | Q28141482 | ||
| Short-term treatment of recombinant murine interleukin-4 rapidly inhibits bone formation in normal and ovariectomized mice | Q74472393 | ||
| Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells | Q74520565 | ||
| A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2 | Q74595874 | ||
| Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation | Q74802758 | ||
| Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells | Q77484251 | ||
| Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women | Q79762888 | ||
| Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts | Q79894176 | ||
| Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway | Q80637499 | ||
| Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways | Q80763818 | ||
| Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation | Q80809164 | ||
| Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway | Q81406086 | ||
| IL-18 inhibits TNF-alpha-induced osteoclastogenesis possibly via a T cell-independent mechanism in synergy with IL-12 in vivo | Q82690947 | ||
| Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis | Q82812696 | ||
| Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes | Q83022902 | ||
| Immune system and bone metabolism: Does thymectomy influence postmenopausal bone loss in humans? | Q83322481 | ||
| IFN-γ directly inhibits TNF-α-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions | Q83455142 | ||
| IL-12- and IL-18-mediated, nitric oxide-induced apoptosis in TNF-α-mediated osteoclastogenesis of bone marrow cells | Q84193047 | ||
| IL-12 inhibits TNF-alpha induced osteoclastogenesis via a T cell-independent mechanism in vivo | Q84340890 | ||
| Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women | Q84346497 | ||
| Bone resorption by osteoclasts | Q28145169 | ||
| RANK-L and RANK: T cells, bone loss, and mammalian evolution | Q28203468 | ||
| Evidence for osteocyte regulation of bone homeostasis through RANKL expression | Q28247757 | ||
| Estrogen regulation of immune cell bone interactions | Q28251201 | ||
| Interleukin-11 receptor signaling is required for normal bone remodeling | Q28254984 | ||
| Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems | Q28294477 | ||
| Heritable disorders of the RANKL/OPG/RANK signaling pathway | Q28299674 | ||
| Interleukin-32: a cytokine and inducer of TNFalpha | Q28303648 | ||
| IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells | Q28591227 | ||
| Interleukin-4 directly inhibits tumor necrosis factor-alpha-mediated osteoclast formation in mouse bone marrow macrophages | Q28592011 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages | Q29618421 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Cytoskeletal dysfunction dominates in DAP12-deficient osteoclasts | Q30496147 | ||
| Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway | Q33228319 | ||
| Effect of interleukin-10 on gene expression of osteoclastogenic regulatory molecules in the rat dental follicle | Q33233181 | ||
| Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus | Q33269870 | ||
| Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alpha-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. | Q33790174 | ||
| Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction | Q33886695 | ||
| Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. | Q33920086 | ||
| Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo | Q33950241 | ||
| The immune system. First of two parts | Q33959636 | ||
| The immune system. Second of two parts | Q33966058 | ||
| Interleukin 15: biology and relevance to human disease | Q34116304 | ||
| M-CSF mediates TNF-induced inflammatory osteolysis | Q34133595 | ||
| Interleukin-11: a new cytokine critical for osteoclast development | Q34138407 | ||
| Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets | Q34283578 | ||
| Long-term treatment of osteopetrosis with recombinant human interferon gamma | Q34310828 | ||
| The role of cytokines in osteoarthritis pathophysiology | Q34524517 | ||
| Changes in proinflammatory cytokine activity after menopause | Q34530773 | ||
| Signaling crosstalk between RANKL and interferons in osteoclast differentiation | Q34731222 | ||
| Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 | ||
| Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy | Q35083970 | ||
| OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice | Q35187075 | ||
| IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation | Q35219971 | ||
| IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. | Q37497970 | ||
| Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells | Q37531252 | ||
| The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase | Q37647341 | ||
| The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis | Q37699176 | ||
| New treatment targets in osteoporosis | Q37728319 | ||
| Cell biology of osteoimmunology. | Q37780490 | ||
| A controversial role for IL-12 in immune response and bone resorption at apical periodontal sites. | Q37847056 | ||
| Interleukin-23: a key cytokine in inflammatory diseases | Q37876404 | ||
| Transforming growth factor-beta increases interleukin-6 transcripts in osteoblasts | Q38314616 | ||
| IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model | Q38500014 | ||
| Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. | Q38594831 | ||
| Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells | Q39645392 | ||
| IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells | Q39756550 | ||
| Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells | Q40107693 | ||
| Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis. | Q40186866 | ||
| Murine dendritic cell transdifferentiation into osteoclasts is differentially regulated by innate and adaptive cytokines | Q40241909 | ||
| Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system | Q40256895 | ||
| RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis an | Q40292785 | ||
| Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides | Q40332321 | ||
| Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis. | Q40449567 | ||
| Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. | Q40477297 | ||
| A Rapid Multiparameter Approach to Study Factors that Regulate Osteoclastogenesis: Demonstration of the Combinatorial Dominant Effects of TNF-α and TGF-ß in RANKL-Mediated Osteoclastogenesis | Q40630232 | ||
| Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells | Q40710871 | ||
| TGF-beta1 and IFN-gamma cross-regulate antigen presentation to CD4 T cells by macrophages | Q40720267 | ||
| IL-6 negatively regulates IL-11 production in vitro and in vivo | Q40784684 | ||
| IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro | Q40814402 | ||
| Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation | Q40818408 | ||
| Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis | Q40823079 | ||
| Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells | Q40827144 | ||
| The cellular actions of interleukin-11 on bone resorption in vitro | Q40864547 | ||
| IL-1 mediates TNF-induced osteoclastogenesis | Q40909592 | ||
| Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells | Q40927574 | ||
| OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. | Q40991620 | ||
| IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures | Q41055042 | ||
| IL-6 is produced by osteoblasts and induces bone resorption | Q41714818 | ||
| Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction | Q41927546 | ||
| Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation | Q42219222 | ||
| Interleukin-17: A new bone acting cytokine in vitro | Q42476956 | ||
| Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. | Q42526719 | ||
| T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis | Q42601982 | ||
| Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells | Q43470520 | ||
| Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. | Q44073722 | ||
| IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae | Q44129538 | ||
| Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis | Q44514609 | ||
| Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis | Q44985215 | ||
| The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study | Q45247132 | ||
| Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. | Q45274056 | ||
| 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. | Q46008001 | ||
| Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo | Q46265274 | ||
| Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. | Q47687944 | ||
| Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis | Q47761859 | ||
| Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro | Q47914319 | ||
| Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy | Q48024087 | ||
| Proinflammatory agents, IL-8 and IL-10, upregulate inducible nitric oxide synthase expression and nitric oxide production in avian osteoclast-like cells | Q48065548 | ||
| A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis | Q49174472 | ||
| Gene deletion of either interleukin-1beta, interleukin-1beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament | Q50491685 | ||
| Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. | Q50674392 | ||
| IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro. | Q51022810 | ||
| IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. | Q51680495 | ||
| Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership? | Q51778025 | ||
| Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. | Q51802618 | ||
| Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-γ possibly induced from non-T cell population | Q51813167 | ||
| Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. | Q51994210 | ||
| A novel function of interleukin-10 promoting self-renewal of hematopoietic stem cells. | Q52578758 | ||
| Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro. | Q53581241 | ||
| T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. | Q53597060 | ||
| Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis | Q35552303 | ||
| Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha | Q35553437 | ||
| B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo | Q35804512 | ||
| The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues | Q35838186 | ||
| Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. | Q35918333 | ||
| CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts | Q35955973 | ||
| Osteoblast-specific overexpression of human interleukin-7 rescues the bone mass phenotype of interleukin-7-deficient female mice | Q35992094 | ||
| Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. | Q36085011 | ||
| Transforming growth factor-beta1 to the bone | Q36131663 | ||
| Interplay between interferon and other cytokine systems in bone metabolism | Q36324962 | ||
| TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 | ||
| Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis | Q36402845 | ||
| The stem cell niches in bone | Q36467113 | ||
| Interleukin-7 induced immunopathology in arthritis | Q36622402 | ||
| Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis | Q36632162 | ||
| The molecular understanding of osteoclast differentiation | Q36650749 | ||
| Osteoporosis induced in mice by overproduction of interleukin 4. | Q36716814 | ||
| Cytokine targeting in osteoarthritis | Q36737779 | ||
| In vivo osteoarthritis target validation utilizing genetically-modified mice | Q36737812 | ||
| TGF-beta and osteoarthritis | Q36773157 | ||
| Estrogen deficiency, T cells and bone loss | Q36948752 | ||
| Osteoporosis and inflammation | Q37073877 | ||
| Interleukin-1 and interleukin-1 antagonism | Q37081535 | ||
| Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha | Q37271202 | ||
| TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation | Q37307155 | ||
| Evidence that cytokines play a role in rheumatoid arthritis | Q37316594 | ||
| IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression | Q37342418 | ||
| RANK/RANKL: regulators of immune responses and bone physiology | Q37348448 | ||
| Ovariectomy selectively reduces the concentration of transforming growth factor beta in rat bone: implications for estrogen deficiency-associated bone loss | Q37353908 | ||
| Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency | Q37365710 | ||
| Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. | Q37377903 | ||
| Interleukin-6 as a key player in systemic inflammation and joint destruction. | Q37384484 | ||
| TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand | Q37413745 | ||
| Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. | Q53941037 | ||
| Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice. | Q53955397 | ||
| Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. | Q53968745 | ||
| Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors. | Q53993822 | ||
| Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. | Q54041247 | ||
| Interleukin 4 inhibits murine osteoclast formation in vitro. | Q54286289 | ||
| Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. | Q54399590 | ||
| Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. | Q54420652 | ||
| TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. | Q55478696 | ||
| Immune Interactions with CD4+ T Cells Promote the Development of Functional Osteoclasts from Murine CD11c+ Dendritic Cells | Q57184758 | ||
| RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β | Q57675150 | ||
| Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling | Q58085461 | ||
| T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ | Q59064307 | ||
| IL-7 Modulates Osteoclastogenesis in Patients Affected by Solid Tumors | Q60041633 | ||
| Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines | Q60524890 | ||
| Interleukin-1α gene variants influence bone mineral density and the risk of osteoporotic hip fractures in elderly Slovenian people | Q60659112 | ||
| Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFα, and IL-7 in anin vitromodel derived from human psoriatic arthritis | Q61043823 | ||
| Inflammaging: The driving force in osteoporosis? | Q61631790 | ||
| Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis | Q64377272 | ||
| Increased osteoclast development after estrogen loss: mediation by interleukin-6 | Q68188964 | ||
| Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro | Q69738552 | ||
| Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro | Q70278203 | ||
| Bone Resorbing Activity in Supernatant Fluid from Cultured Human Peripheral Blood Leukocytes | Q70436209 | ||
| Interleukin-10 inhibits the osteogenic activity of mouse bone marrow | Q70482976 | ||
| IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts | Q70844192 | ||
| Interleukin-6 expression and histomorphometry of bones from mice deficient in receptors for interleukin-1 or tumor necrosis factor | Q71773581 | ||
| Short-term local injections of transforming growth factor-beta 1 decrease ovariectomy-stimulated osteoclastic resorption in vivo in rats | Q71773712 | ||
| Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia | Q72150177 | ||
| IL-4 and IL-13, but not IL-10, are chemotactic factors for human osteoblasts | Q72233860 | ||
| Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention | Q73010765 | ||
| Interferon-alpha, unlike interferon-gamma, does not cause bone loss in the rat | Q73052699 | ||
| Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis | Q73067239 | ||
| Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis | Q73072111 | ||
| Activated T lymphocytes support osteoclast formation in vitro | Q73149439 | ||
| Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice | Q73370075 | ||
| Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts | Q73441763 | ||
| Bone malformations in interleukin-18 transgenic mice | Q73554430 | ||
| Bone marrow as a priming site for T-cell responses to blood-borne antigen | Q73791481 | ||
| Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients | Q73880310 | ||
| Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast forma | Q74148039 | ||
| Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines | Q74269794 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immune system | Q1059 |
| inflammation | Q101991 | ||
| peptide | Q172847 | ||
| cytokine | Q212354 | ||
| cell | Q7868 | ||
| bone disease | Q4941552 | ||
| inflammation mediators | Q66765004 | ||
| hemic and immune systems | Q70202933 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 43-63 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Biochemia Medica | Q15746691 |
| P1476 | title | Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts | |
| P478 | volume | 23 |
| Q39317301 | A Truncated IL-17RC Peptide Ameliorates Synovitis and Bone Destruction of Arthritic Mice |
| Q51684688 | Acute effects of dietary fatty acids on osteclastogenesis via RANKL/RANK/OPG system. |
| Q89964126 | Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice via Modulation of NFATc1 |
| Q54257351 | Anti-HMGB1 Neutralizing Antibody Attenuates Periodontal Inflammation and Bone Resorption in a Murine Periodontitis Model. |
| Q28066397 | Bone Cells Dynamics during Peri-Implantitis: a Theoretical Analysis |
| Q36560200 | Changing expression profiles of lncRNAs, mRNAs, circRNAs and miRNAs during osteoclastogenesis |
| Q86044703 | Characterization of DC-STAMP+ Cells in Human Bone Marrow |
| Q43528346 | Chronic arsenic intoxication diagnostic score (CAsIDS). |
| Q48609559 | Chronological differential effects of pro-inflammatory cytokines on RANKL-induced osteoclast differentiation of canine bone marrow-derived macrophages |
| Q92888941 | Circulatory Levels of RANKL, OPG, and Oxidative Stress Markers in Postmenopausal Women With Normal or Low Bone Mineral Density |
| Q88389971 | Correlation of Serum CCL3/MIP-1α Levels with Disease Severity in Postmenopausal Osteoporotic Females |
| Q38698754 | Could cytokine levels in the peri-implant crevicular fluid be used to distinguish between healthy implants and implants with peri-implantitis? A systematic review |
| Q92882749 | Does Allergy Break Bones? Osteoporosis and Its Connection to Allergy |
| Q58132286 | Effect of C-3102 on bone mineral density in healthy postmenopausal Japanese women: a randomized, placebo-controlled, double-blind clinical trial |
| Q36245404 | Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis. |
| Q35535372 | Evaluation of the protective effects of curcuminoid (curcumin and bisdemethoxycurcumin)-loaded liposomes against bone turnover in a cell-based model of osteoarthritis |
| Q35210243 | Gene expression profiling of peri-implant healing of PLGA-Li+ implants suggests an activated Wnt signaling pathway in vivo |
| Q39026321 | HIV-1 replicates in human osteoclasts and enhances their differentiation in vitro |
| Q99550095 | Hafnium (IV) oxide obtained by atomic layer deposition (ALD) technology promotes early osteogenesis via activation of Runx2-OPN-mir21A axis while inhibits osteoclasts activity |
| Q37271285 | IL-18BP is decreased in osteoporotic women: Prevents Inflammasome mediated IL-18 activation and reduces Th17 differentiation |
| Q88054294 | In vitro isolation and cultivation of human chondrocytes for osteoarthritis renovation |
| Q36142219 | Increased levels of interleukin 31 (IL-31) in osteoporosis |
| Q38218977 | Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis |
| Q28817706 | Inflammation as a contributing factor among postmenopausal Saudi women with osteoporosis |
| Q40670485 | Inflammatory Markers and the Risk of Hip and Vertebral Fractures in Men: the Osteoporotic Fractures in Men (MrOS). |
| Q38177684 | Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing |
| Q58133794 | Interleukin-17A Levels Increase in Serum of Children With Juvenile Idiopathic Arthritis |
| Q37581596 | Interleukin-32 Gamma Stimulates Bone Formation by Increasing miR-29a in Osteoblastic Cells and Prevents the Development of Osteoporosis |
| Q41943716 | Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis |
| Q38716121 | Lipoxin A4 suppresses osteoclastogenesis in RAW264.7 cells and prevents ovariectomy-induced bone loss |
| Q55533759 | Loss of murine Gfi1 causes neutropenia and induces osteoporosis depending on the pathogen load and systemic inflammation. |
| Q90418789 | Multivariate Comparison of Cytokine Profiles for Normal- and Low-Bone-Density Subjects |
| Q35899482 | Nur77 prevents excessive osteoclastogenesis by inducing ubiquitin ligase Cbl-b to mediate NFATc1 self-limitation. |
| Q37548012 | Osteoimmunology and Beyond |
| Q59793165 | Osteoimmunology of tumor necrosis factor-alpha, IL-6, and RANTES/CCL5: a review of known and poorly understood inflammatory patterns in osteonecrosis |
| Q53211177 | Polycan suppresses osteoclast differentiation and titanium particle-induced osteolysis in mice. |
| Q88592126 | Soluble Tumor Necrosis Factor Alpha Receptor 1, Bone Resorption, and Bone Mineral Density in the Year Following Hip Fractures: The Baltimore Hip Studies |
| Q37236070 | The Effect of Long-Term Exercise on the Production of Osteoclastogenic and Antiosteoclastogenic Cytokines by Peripheral Blood Mononuclear Cells and on Serum Markers of Bone Metabolism |
| Q48079300 | The Inhibitory Effect of Angelica tenuissima Water Extract on Receptor Activator of Nuclear Factor-Kappa-B Ligand-Induced Osteoclast Differentiation and Bone Resorbing Activity of Mature Osteoclasts |
| Q26773017 | The Modulatory Effects of Mesenchymal Stem Cells on Osteoclastogenesis |
| Q94076947 | The Natural Product 6-Gingerol Inhibits Inflammation-Associated Osteoclast Differentiation via Reduction of Prostaglandin E₂ Levels |
| Q91611014 | The Role of Macrophage in the Pathogenesis of Osteoporosis |
| Q29247902 | The association between major depressive disorder, use of antidepressants and bone mineral density (BMD) in men |
| Q50438614 | WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice. |
Search more.